SLC22A16

Across TCGA pan-cancer cohorts, SLC22A16 Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated SLC22A16 data layer compared with 26 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher SLC22A16 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SLC22A16 expression acts as an unfavorable survival marker.

MESO, PAAD, and BRCA are the cancer types where SLC22A16 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Median	III,IV	0.098	0.579	.001	36	view →
PAAD	OS	Median	All	0.112	0.613	<.001	24	view →
BRCA	DFS	Median	All	0.644	0.903	<.001	18	view →
THCA	DFS	Median	All	0.118	0.829	.001	15	view →
BLCA	DFS	Median	All	0.078	0.594	<.001	9	view →
LUSC	OS	Median	III,IV	0.178	0.683	.040	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
COAD	OS	Median	All	0.527	0.872	.016	1	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

SLC22A16–MESO (OS)

Open the MESO breakdown →